Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03946683 · ClinicalTrials.gov registry record · NA
Cyberknife for Early Stage Breast Cancer
A NA study, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
NCT03946683 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 26 participants.
The verdict
NCT03946683, a NA study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
Study Summary
This phase II study based on the Cyberknife Society study will evaluate the technical feasibility and acute toxicity of Partial Breast Irradiation (PBI) with the Cyberknife. It will evaluate quality of life (QOL) issues as they relate to treatment-related side effects, cosmetic result and patient convenience. It will evaluate outcome in terms of local control in the treated breast. Radiosurgery is defined as the stereotactic delivery of ionizing radiation in 5 stages or less to a designated target with sub-millimeter accuracy. Radiosurgery in the context of this protocol will be given to the region of the tumor bed with 7 weeks of the lumpectomy and sent/axillary node sampling over the period of five to ten days using the Cyberknife (CK) or within the 7 weeks of the last chemotherapy treatment if given.
Interventions
- RADIATION Cyberknife for Early Stage Breast Cancer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2010-09 |
| Est. Completion | 2020-04-23 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03946683
The ClinicalTrials.gov registry entry for NCT03946683 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cyberknife for Early Stage Breast Cancer is the first listed.
NCT03946683 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03946683 about?
NCT03946683 is a clinical study titled "Cyberknife for Early Stage Breast Cancer". This phase II study based on the Cyberknife Society study will evaluate the technical feasibility and acute toxicity of Partial Breast Irradiation (PBI) with the Cyberknife. It will evaluate quality of life (QOL) issues as they relate to treatment-related side effects, cosmetic result and patient co...
What is the current status of trial NCT03946683?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2010-09. Estimated completion is 2020-04-23.
What interventions are being tested in trial NCT03946683?
The interventions under investigation include: Cyberknife for Early Stage Breast Cancer (RADIATION).
Who is sponsoring clinical trial NCT03946683?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.